On one hand, Foxp3 directly inhibits the activity of the VEGF promoter through a specific forkhead binding motif, which leads to the inhibition of angiogenesis in breast cancer by suppressing the expression of VEGF, consequently downregulating VEGF (49); On the other hand, Foxp3 binds to the promoter of CD44 coding gene to suppress breast cancer metastasis, thereby hindering the progress of breast cancer (50). Here, VEGFA is linked to breast cancer.